Vasculitis and Giant Cell Arteritis News

Incidence of Henoch-Schönlein purpura waned and waxed significantly with the implementation and relaxation of non-pharmaceutical interventions against COVID-19, according to data published in JAMA Network Open.

All diagnoses of giant cell arteritis made through temporal artery ultrasound were unchanged at 1 month — and at 2 years, for those with available data — in a study published in Annals of Internal Medicine.

A new metric reliably confirms giant cell arteritis in suspected cases by combining a validated clinical scoring tool with ultrasonography, according to data in The Lancet Rheumatology.

Nearly half of patients with giant cell arteritis who received upadacitinib while tapering steroids achieved remission from weeks 12 through 52 in a phase 3 trial, according to a press release from AbbVie.

Higher scores on a measure of sinonasal symptoms can predict ANCA-associated vasculitis relapse “months to years” ahead of time, according data published in Arthritis Care & Research.

This episode digs into the pathophysiology of urticaria vasculitis from anti-C1q to the story of bradykinin.

Since the beginning of the COVID-19 pandemic, there has been a “significant decrease” in the risk for post-acute sequelae of COVID-19 among patients with rheumatic diseases, according to data published in The Journal of Rheumatology.

Patients with prior sinusitis demonstrate an increased risk for many rheumatic diseases, including antiphospholipid syndrome, Sjögren’s disease and seronegative rheumatoid arthritis, according to data published in RMD Open.

Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The New England Journal of Medicine.

Patients who eventually developed giant cell arteritis demonstrated significantly higher levels of apolipoprotein A-I at baseline, according to population-based data published in Arthritis Research & Therapy.